Literature DB >> 16686675

Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current.

Albertas I Undrovinas1, Luiz Belardinelli, Nidas A Undrovinas, Hani N Sabbah.   

Abstract

BACKGROUND: Ventricular repolarization and contractile function are frequently abnormal in ventricular myocytes from human failing hearts as well as canine hearts with experimentally induced heart failure (HF). These abnormalities have been attributed to dysfunction involving various steps of the excitation-contraction coupling process, leading to impaired intracellular sodium and calcium homeostasis. We previously reported that the slow inactivating component of the Na(+) current (late I(Na)) is augmented in myocytes from failing hearts, and this appears to play a significant role in abnormal ventricular myocytes repolarization and function. We tested the effect of ranolazine, a novel drug being developed to treat angina, on (1) action potential duration (APD), (2) peak transient and late I(Na) (I(NaT) and I(NaL), respectively), (3) early afterdepolarizations (EADs), and (4) twitch contraction (TC), including after contractions and contracture.
METHODS: Myocytes were isolated from the left ventricle of normal dogs and of dogs with chronic HF caused by multiple sequential intracoronary micro-embolizations. I(NaT) and I(NaL) were recorded using conventional whole-cell patch-clamp techniques. APs were recorded using the beta-escin perforated patch-clamp configuration at frequencies of 0.25 and 0.5 Hz. TCs were recorded using an edge movement detector at stimulation frequencies ranging from 0.5 to 2.0 Hz.
RESULTS: Ranolazine significantly (P<0.05) and reversibly shortened the APD of myocytes stimulated at either 0.5 or 0.25 Hz in a concentration-dependent manner. At a stimulation frequency of 0.5 Hz, 5, 10, and 20 microM ranolazine shortened the APD(90) (APD measured at 90% repolarization) from 516+/-51 to 304+/-22, 212+/-34 and 160+/-11 ms, respectively, and markedly decreased beat-to-beat variability of APD(90), EADs, and dispersion of APDs. Ranolazine preferentially blocked I(NaL) relative to I(NaT) in a state-dependent manner, with a approximately 38-fold greater potency against I(NaL) to produce tonic block (IC(50)=6.5 microM) than I(NaT) (IC(50)=294 microM). When we evaluated inactivated state blockade of I(NaL) from the steady-state inactivation mid-potential shift using a theoretical model, ranolazine was found to bind more tightly to the inactivated state than the resting state of the sodium channel underlying I(NaL), with apparent dissociation constants K(dr)=7.47 microM and K(di)=1.71 microM, respectively. TCs of myocytes stimulated at 0.5 Hz were characterized by an initial spike followed by a dome-like after contraction, which was observed in 75% of myocytes from failing hearts and coincided with the long AP plateau and EADs. Ranolazine at 5 and 10 microM reversibly shortened the duration of TCs and abolished the after contraction. When the rate of myocyte stimulation was increased from 1.0 to 2.0 Hz, there was a progressive increase in diastolic "tension," that is, contracture. Ranolazine at 5 and 10 microM reversibly prevented this frequency-dependent contracture.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16686675      PMCID: PMC1482456          DOI: 10.1111/j.1540-8167.2006.00401.x

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  30 in total

Review 1.  Electrophysiological remodeling in hypertrophy and heart failure.

Authors:  G F Tomaselli; E Marbán
Journal:  Cardiovasc Res       Date:  1999-05       Impact factor: 10.787

2.  Gating of the late Na+ channel in normal and failing human myocardium.

Authors:  Albertas I Undrovinas; Victor A Maltsev; John W Kyle; Norman Silverman; Hani N Sabbah
Journal:  J Mol Cell Cardiol       Date:  2002-11       Impact factor: 5.000

3.  [Na+]i and the driving force of the Na+/Ca2+-exchanger in heart failure.

Authors:  A Baartscheer; C A Schumacher; C N W Belterman; R Coronel; J W T Fiolet
Journal:  Cardiovasc Res       Date:  2003-03-15       Impact factor: 10.787

4.  A multi-modal composition of the late Na+ current in human ventricular cardiomyocytes.

Authors:  Victor A Maltsev; Albertas I Undrovinas
Journal:  Cardiovasc Res       Date:  2005-10-11       Impact factor: 10.787

5.  Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes.

Authors:  Yejia Song; John C Shryock; Lin Wu; Luiz Belardinelli
Journal:  J Cardiovasc Pharmacol       Date:  2004-08       Impact factor: 3.105

6.  Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.

Authors:  Bernard R Chaitman; Carl J Pepine; John O Parker; Jaroslav Skopal; Galina Chumakova; Jerzy Kuch; Whedy Wang; Sandra L Skettino; Andrew A Wolff
Journal:  JAMA       Date:  2004-01-21       Impact factor: 56.272

7.  Rate dependence of [Na+]i and contractility in nonfailing and failing human myocardium.

Authors:  Burkert Pieske; Lars S Maier; Valentino Piacentino; Jutta Weisser; Gerd Hasenfuss; Steven Houser
Journal:  Circulation       Date:  2002-07-23       Impact factor: 29.690

8.  Down-regulation of sodium current in chronic heart failure: effect of long-term therapy with carvedilol.

Authors:  V A Maltsev; H N Sabbab; A I Undrovinas
Journal:  Cell Mol Life Sci       Date:  2002-09       Impact factor: 9.261

9.  Relations among heart failure severity, left ventricular loading conditions, and repolarization length in advanced heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.

Authors:  Fernando Boccalandro; Andres Velasco; Cindy Thomas; Barbara Richards; Branislav Radovancevic
Journal:  Am J Cardiol       Date:  2003-09-01       Impact factor: 2.778

10.  Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina.

Authors:  Bernard R Chaitman; Sandra L Skettino; John O Parker; Peter Hanley; Jaroslav Meluzin; Jerzy Kuch; Carl J Pepine; Whedy Wang; Jeanenne J Nelson; David A Hebert; Andrew A Wolff
Journal:  J Am Coll Cardiol       Date:  2004-04-21       Impact factor: 24.094

View more
  112 in total

1.  Y1767C, a novel SCN5A mutation, induces a persistent Na+ current and potentiates ranolazine inhibition of Nav1.5 channels.

Authors:  Hai Huang; Silvia G Priori; Carlo Napolitano; Michael E O'Leary; Mohamed Chahine
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-11-12       Impact factor: 4.733

2.  AMPK Activation by Metformin Promotes Survival of Dormant ER+ Breast Cancer Cells.

Authors:  Riley A Hampsch; Jason D Wells; Nicole A Traphagen; Charlotte F McCleery; Jennifer L Fields; Kevin Shee; Lloye M Dillon; Darcy B Pooler; Lionel D Lewis; Eugene Demidenko; Yina H Huang; Jonathan D Marotti; Abigail E Goen; William B Kinlaw; Todd W Miller
Journal:  Clin Cancer Res       Date:  2020-04-22       Impact factor: 12.531

3.  From the Hodgkin-Huxley axon to the virtual heart.

Authors:  Denis Noble
Journal:  J Physiol       Date:  2006-10-05       Impact factor: 5.182

Review 4.  Ranolazine: a review of its use as add-on therapy in patients with chronic stable angina pectoris.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2013-01       Impact factor: 9.546

5.  Ranolazine prevents pressure overload-induced cardiac hypertrophy and heart failure by restoring aberrant Na+ and Ca2+ handling.

Authors:  Jiali Nie; Quanlu Duan; Mengying He; Xianqing Li; Bei Wang; Chi Zhou; Lujin Wu; Zheng Wen; Chen Chen; Dao Wu Wang; Katherina M Alsina; Xander H T Wehrens; Dao Wen Wang; Li Ni
Journal:  J Cell Physiol       Date:  2018-11-29       Impact factor: 6.384

6.  Synergistic electrophysiologic and antiarrhythmic effects of the combination of ranolazine and chronic amiodarone in canine atria.

Authors:  Serge Sicouri; Alexander Burashnikov; Luiz Belardinelli; Charles Antzelevitch
Journal:  Circ Arrhythm Electrophysiol       Date:  2009-12-01

7.  Novel pharmacological approaches for antiarrhythmic therapy.

Authors:  Ursula Ravens
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-01-15       Impact factor: 3.000

Review 8.  Late sodium current is a new therapeutic target to improve contractility and rhythm in failing heart.

Authors:  Albertas Undrovinas; Victor A Maltsev
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2008-10

9.  Modulation of late sodium current by Ca2+, calmodulin, and CaMKII in normal and failing dog cardiomyocytes: similarities and differences.

Authors:  Victor A Maltsev; Vitaliy Reznikov; Nidas A Undrovinas; Hani N Sabbah; Albertas Undrovinas
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-01-18       Impact factor: 4.733

Review 10.  Voltage-gated sodium channels: pharmaceutical targets via anticonvulsants to treat epileptic syndromes.

Authors:  Mena Abdelsayed; Stanislav Sokolov
Journal:  Channels (Austin)       Date:  2013-03-26       Impact factor: 2.581

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.